Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

Dopamine promotes GH release through activation of dopamine D2 receptors (D2Rs).

Who Took Part

The study group was 18 women.

The age groups tagged for this paper are adults and middle-aged adults, women only.

Eight days of treatment with B and placebo (Pl) was performed.

How the Study Was Run

The design is described as placebo-controlled and crossover.

Some women received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

In the crossover set-up each of the women took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

This was a prospective, fixed order, cross-over study.

The study was performed in the Clinical Research Center at Leiden University Medical Center.

What Was Measured

The subject headings attached to it are Bromocriptine, Chronobiology Disorders, Circadian Rhythm, Dopamine Agonists, Human Growth Hormone, Insulin and Leptin.

What This Means in Plain Language

The paper is a placebo-controlled and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2008 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.